| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(18)30859-3 |
| P698 | PubMed publication ID | 30745090 |
| P50 | author | Brian Slomovitz | Q123915583 |
| Morten Mau-Sorensen | Q47424313 | ||
| James Spicer | Q86599148 | ||
| P2093 | author name string | Johann S de Bono | |
| Ulrik Lassen | |||
| Joo Ern Ang | |||
| Nicole Concin | |||
| David S Hong | |||
| Ruth Plummer | |||
| Hendrik-Tobias Arkenau | |||
| Jean-Pascal Machiels | |||
| Jeffrey Yachnin | |||
| Dorte Nielsen | |||
| Reshma A Rangwala | |||
| Srinivas Ghatta | |||
| Dearbhaile Collins | |||
| Fiona C Thistlethwaite | |||
| Emma Dean | |||
| Kristian Windfeld | |||
| Martin David Forster | |||
| Robert Hugh Jones | |||
| P2860 | cites work | Tissue factor predicts response to chemotherapy in esophageal cancer | Q87730446 |
| Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies | Q21131216 | ||
| New developments for antibody-drug conjugate-based therapeutic approaches | Q26766540 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor | Q33938673 | ||
| hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. | Q34253625 | ||
| Tissue factor, blood coagulation, and beyond: an overview | Q35222618 | ||
| Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor | Q36972097 | ||
| Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma | Q37279128 | ||
| Role of tissue factor in cancer | Q37393391 | ||
| The relationship between tissue factor and cancer progression: insights from bench and bedside | Q37953890 | ||
| Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study | Q38422779 | ||
| Tissue Factor: Old and New Links with Cancer Biology. | Q38593289 | ||
| Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates | Q38798481 | ||
| High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates | Q38905336 | ||
| Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma | Q40438100 | ||
| Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. | Q40943118 | ||
| Tissue factor expression and prognosis in patients with metastatic prostate cancer | Q44686290 | ||
| Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk | Q45150436 | ||
| An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors | Q45231931 | ||
| Isolation, Detection, and Antigen-Based Profiling of Circulating Tumor Cells Using a Size-Dictated Immunocapture Chip. | Q47202441 | ||
| Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient | Q47845503 | ||
| Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. | Q54145263 | ||
| Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer | Q80145540 | ||
| A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies | Q82489143 | ||
| Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events | Q83780867 | ||
| P433 | issue | 3 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 383-393 | |
| P577 | publication date | 2019-02-08 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial | |
| P478 | volume | 20 |
| Q90681595 | Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial |
| Q90171337 | Exploiting the folate receptor α in oncology |
| Q98386332 | Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy |
| Q92366436 | Precision medicine for human cancers with Notch signaling dysregulation (Review) |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q91465889 | Targeting tissue factor in advanced solid tumours |
| Q89767304 | Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer |
| Q90170947 | Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis |
| Q90325608 | [Monoclonal antibodies] |
Search more.